Fabtech Technologies Limited – Investor Presentation Summary

Key Operational Highlights

  • Delivered projects in 62+ countries with 500+ projects completed and 2000+ specialised installations.
  • Maintained operational continuity despite freight volatility, geopolitical disruption, and elevated input costs.
  • Consolidated order book of ₹900+ crore as of March 31, 2026, providing strong revenue visibility.
  • Expanded regional presence with localisation in UAE and Saudi Arabia, joint ventures, and a European acquisition.

Key drivers of operational performance: Project execution momentum, strategic wins in new segments like animal health, and control over timeline through pre-engineered building scope.

Segment-wise Performance

Not specified in the presentation.

Financial Highlights

  • Revenue: ₹410.77 crore, up 25.7% YoY from ₹326.67 crore in FY25.
  • Operational Profit: ₹36.60 crore, up 17.0% YoY from ₹31.27 crore in FY25 (note: includes impact from 16.66% of TSA sale).
  • PAT: ₹38.36 crore, compared to ₹46.45 crore in FY25, with normalised exceptionals.
  • Margins: Operational profit margin approximately 8.9%, PAT margin approximately 9.3%.
  • YoY comparison: Revenue growth driven by project execution, though profit impacted by cost pressures.
  • Drivers of financial performance: Higher revenue growth, partially offset by input cost increases and geopolitical challenges.
  • Comparison to market estimates: Not provided.
  • Key Risks: Geopolitical disruption, freight volatility, and input cost pressures mentioned.

Geographical Revenue Split

  • Domestic vs Export: Approximately 78% of revenue from MENA, GCC, and ECO Zone markets, implying export-heavy focus.
  • Domestic revenue not specified, but likely around 22% or less.
  • Regional Breakdown: Strong presence in Middle East, North Africa, and emerging geographies.

Balance Sheet Snapshot

Not specified in the presentation.

Capex & Cash Flow Health

Not detailed; mentioned capex earmarked by pharmaceutical companies, but no specific figures for Fabtech.

Strategic & R&D Initiatives

  • Investments in Innovation: European acquisition to strengthen brand and enter premium markets, joint ventures in KSA, East Africa, and North Africa.
  • Expected impact on growth: Margin expansion through tax advantages and local-content preferences, targeting PAT margins of 11-13%.
  • Strategic Rationale: Expanding into high-growth markets, reducing operational costs, and diversifying product portfolio.

Industry Trends & Business Environment

  • Macro/Industry Trends: Geopolitical disruption reshaping global supply chains, trend towards regional medicinal sovereignty, funded by WHO/Global Fund initiatives to 2040.
  • Impact on Company: Near-term delivery disruptions and cost increases, but long-term opportunity for outsized gains as companies localize medicine manufacturing.

Management Commentary & Growth Outlook

  • Strategic Outlook: Positive outlook with robust pipeline of complex, high-value projects; aiming to compound shareholder value across cycles.
  • FY Guidance: FY27 standalone revenue target of ₹500 crore, PAT target of ₹45 crore (approximately 9% margin), with expansion towards 11-13% PAT margin.
  • Market Share Targets: Not explicitly provided, but vision to climb value curve to advanced-technology facilities like medical diagnostics, vaccines, biotech, cell & gene therapy, and high-tech facilities.
  • Risks and Opportunities: Risks include input cost hikes and geopolitical issues; opportunities include structural shift towards regional medicinal sovereignty over 15 years.